FiercePharma6h
Quantoom, Univercells and Fiocruz ink collaboration to bolster RNA-based vaccines in Brazil and beyond
Belgium mRNA specialist Quantoom Biosciences and biologics manufacturing specialist Univercells inked a partnership deal with ...
FiercePharma7h
Sanofi charts biggest China investment to date with plans for €1B insulin 'manufacturing base' in Beijing
Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing ...
FiercePharma7h
GSK takes AMR message to Paddington, bearing responsibility for raising awareness of risks
GSK has brought its message about the risks of antimicrobial resistance (AMR) to commuters in London. | GSK has brought its ...
FiercePharma11h
FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports
The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and ...
FiercePharma9h
Race is on for oral obesity drugs with multiple phase 3 trials vying for next-gen status in a $126B market
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...
FiercePharma10h
Time to manage dengue with multi-faceted approach
| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of ...
FiercePharma3h
After temporary reprieve, Advanz Pharma's liver med Ocaliva loses marketing nod in Europe
After a rough few months for Intercept and Advanz Pharma's Ocaliva on both sides of the Atlantic, the other shoe has dropped for the rare liver disease drug in Europe. | The General Court of the ...